Protection from apoptotic cell death by interleukin-4 is increased in previously treated chronic lymphocytic leukemia patients

Oskar S. Frankfurt, John Byrnes, Luis Villa

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Chronic lymphocytic leukemia (CLL) cells were cultured in a medium supplemented with 0.01-1 ng/ml interleukin-4 (lL-4) for 18 h, fixed and analyzed on a flow cytometer. The percentage of apoptotic (AP) cells with hypodiploid DNA content was determined from DNA histograms. lL-4 at 0.01 ng/ml protected from spontaneous apoptosis of cells from previously treated CLL patients, but had very little effect on apoptotic death in cultures of cells from untreated patients. The number of AP cells in the absence of IL-4 was similar in cultures from treated and untreated patients. The concentration of IL-4 which inhibited spontaneous apoptosis by 50% was less than 0.01 ng/ml for pretreated patients and close to 1 ng/ml for untreated patients. Stage of the disease had no effect on the level of spontaneous apoptosis and its sensitivity to IL-4. Protection from apoptosis by lL-4 was not accompanied by the upregulation of bcl-2 protein. The number of AP cells in methylprednisolone hemisuccinate (MP) treated cultures from previously treated patients was significantly lower than in cultures from untreated patients in the presence of 0.01-1.0 ng/ml IL-4. Treatment with the combination L-phenylalanine mustard (L-PAM)+fludarabine induced synergistic apoptotic response. Apoptosis induced by this combination was relatively resistant to lL-4 in patients treated with chlorambucil and prednisone, but not in patients previously treated with fludarabine. Protection from cytotoxicity by IL-4 may be one of the mechanisms of acquired drug resistance in CLL.

Original languageEnglish
Pages (from-to)9-16
Number of pages8
JournalLeukemia Research
Volume21
Issue number1
DOIs
StatePublished - Jan 1 1997

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Interleukin-4
Cell Death
Apoptosis
Cell Count
Methylprednisolone Hemisuccinate
Chlorambucil
Melphalan
DNA
Prednisone
Phenylalanine
Drug Resistance
Cultured Cells
Up-Regulation
Cell Culture Techniques

Keywords

  • Apoptosis
  • Chronic lymphocytic leukemia
  • Interleukin-4

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Protection from apoptotic cell death by interleukin-4 is increased in previously treated chronic lymphocytic leukemia patients. / Frankfurt, Oskar S.; Byrnes, John; Villa, Luis.

In: Leukemia Research, Vol. 21, No. 1, 01.01.1997, p. 9-16.

Research output: Contribution to journalArticle

@article{8180f93b719840bdb62b4c3de5f5c32e,
title = "Protection from apoptotic cell death by interleukin-4 is increased in previously treated chronic lymphocytic leukemia patients",
abstract = "Chronic lymphocytic leukemia (CLL) cells were cultured in a medium supplemented with 0.01-1 ng/ml interleukin-4 (lL-4) for 18 h, fixed and analyzed on a flow cytometer. The percentage of apoptotic (AP) cells with hypodiploid DNA content was determined from DNA histograms. lL-4 at 0.01 ng/ml protected from spontaneous apoptosis of cells from previously treated CLL patients, but had very little effect on apoptotic death in cultures of cells from untreated patients. The number of AP cells in the absence of IL-4 was similar in cultures from treated and untreated patients. The concentration of IL-4 which inhibited spontaneous apoptosis by 50{\%} was less than 0.01 ng/ml for pretreated patients and close to 1 ng/ml for untreated patients. Stage of the disease had no effect on the level of spontaneous apoptosis and its sensitivity to IL-4. Protection from apoptosis by lL-4 was not accompanied by the upregulation of bcl-2 protein. The number of AP cells in methylprednisolone hemisuccinate (MP) treated cultures from previously treated patients was significantly lower than in cultures from untreated patients in the presence of 0.01-1.0 ng/ml IL-4. Treatment with the combination L-phenylalanine mustard (L-PAM)+fludarabine induced synergistic apoptotic response. Apoptosis induced by this combination was relatively resistant to lL-4 in patients treated with chlorambucil and prednisone, but not in patients previously treated with fludarabine. Protection from cytotoxicity by IL-4 may be one of the mechanisms of acquired drug resistance in CLL.",
keywords = "Apoptosis, Chronic lymphocytic leukemia, Interleukin-4",
author = "Frankfurt, {Oskar S.} and John Byrnes and Luis Villa",
year = "1997",
month = "1",
day = "1",
doi = "10.1016/S0145-2126(96)00053-7",
language = "English",
volume = "21",
pages = "9--16",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Protection from apoptotic cell death by interleukin-4 is increased in previously treated chronic lymphocytic leukemia patients

AU - Frankfurt, Oskar S.

AU - Byrnes, John

AU - Villa, Luis

PY - 1997/1/1

Y1 - 1997/1/1

N2 - Chronic lymphocytic leukemia (CLL) cells were cultured in a medium supplemented with 0.01-1 ng/ml interleukin-4 (lL-4) for 18 h, fixed and analyzed on a flow cytometer. The percentage of apoptotic (AP) cells with hypodiploid DNA content was determined from DNA histograms. lL-4 at 0.01 ng/ml protected from spontaneous apoptosis of cells from previously treated CLL patients, but had very little effect on apoptotic death in cultures of cells from untreated patients. The number of AP cells in the absence of IL-4 was similar in cultures from treated and untreated patients. The concentration of IL-4 which inhibited spontaneous apoptosis by 50% was less than 0.01 ng/ml for pretreated patients and close to 1 ng/ml for untreated patients. Stage of the disease had no effect on the level of spontaneous apoptosis and its sensitivity to IL-4. Protection from apoptosis by lL-4 was not accompanied by the upregulation of bcl-2 protein. The number of AP cells in methylprednisolone hemisuccinate (MP) treated cultures from previously treated patients was significantly lower than in cultures from untreated patients in the presence of 0.01-1.0 ng/ml IL-4. Treatment with the combination L-phenylalanine mustard (L-PAM)+fludarabine induced synergistic apoptotic response. Apoptosis induced by this combination was relatively resistant to lL-4 in patients treated with chlorambucil and prednisone, but not in patients previously treated with fludarabine. Protection from cytotoxicity by IL-4 may be one of the mechanisms of acquired drug resistance in CLL.

AB - Chronic lymphocytic leukemia (CLL) cells were cultured in a medium supplemented with 0.01-1 ng/ml interleukin-4 (lL-4) for 18 h, fixed and analyzed on a flow cytometer. The percentage of apoptotic (AP) cells with hypodiploid DNA content was determined from DNA histograms. lL-4 at 0.01 ng/ml protected from spontaneous apoptosis of cells from previously treated CLL patients, but had very little effect on apoptotic death in cultures of cells from untreated patients. The number of AP cells in the absence of IL-4 was similar in cultures from treated and untreated patients. The concentration of IL-4 which inhibited spontaneous apoptosis by 50% was less than 0.01 ng/ml for pretreated patients and close to 1 ng/ml for untreated patients. Stage of the disease had no effect on the level of spontaneous apoptosis and its sensitivity to IL-4. Protection from apoptosis by lL-4 was not accompanied by the upregulation of bcl-2 protein. The number of AP cells in methylprednisolone hemisuccinate (MP) treated cultures from previously treated patients was significantly lower than in cultures from untreated patients in the presence of 0.01-1.0 ng/ml IL-4. Treatment with the combination L-phenylalanine mustard (L-PAM)+fludarabine induced synergistic apoptotic response. Apoptosis induced by this combination was relatively resistant to lL-4 in patients treated with chlorambucil and prednisone, but not in patients previously treated with fludarabine. Protection from cytotoxicity by IL-4 may be one of the mechanisms of acquired drug resistance in CLL.

KW - Apoptosis

KW - Chronic lymphocytic leukemia

KW - Interleukin-4

UR - http://www.scopus.com/inward/record.url?scp=0031033449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031033449&partnerID=8YFLogxK

U2 - 10.1016/S0145-2126(96)00053-7

DO - 10.1016/S0145-2126(96)00053-7

M3 - Article

C2 - 9029180

AN - SCOPUS:0031033449

VL - 21

SP - 9

EP - 16

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 1

ER -